Temozolomide and Other Alkylating Agents in Glioblastoma Therapy

by Hannah Strobel, Tim Baisch, Rahel Fitzel, Katharina Schilberg, Markus D. Siegelin, Georg Karpel-Massler, Klaus-Michael Debatin, Mike-Andrew Westhoff
Published 2019-09-01

Uncovering NOTCH1 as a Promising Target in the Treatment of <i>MLL</i>-Rearranged Leukemia

by Jacqueline Fischer, Estelle Erkner, Rahel Fitzel, Pia Radszuweit, Hildegard Keppeler, Fulya Korkmaz, Giovanni Roti, Claudia Lengerke, Dominik Schneidawind, Corina Schneidawind
Published 2023-09-01

Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunity

by Rahel Fitzel, Kathy-Ann Secker-Grob, Hildegard Keppeler, Fulya Korkmaz, Rebekka Schairer, Estelle Erkner, Dominik Schneidawind, Claudia Lengerke, Thomas Hentrich, Julia M. Schulze-Hentrich, Corina Schneidawind
Published 2023-07-01

Considering the Experimental Use of Temozolomide in Glioblastoma Research

by Verena J. Herbener, Timo Burster, Alicia Goreth, Maximilian Pruss, Hélène von Bandemer, Tim Baisch, Rahel Fitzel, Markus D. Siegelin, Georg Karpel-Massler, Klaus-Michael Debatin, Mike-Andrew Westhoff, Hannah Strobel
Published 2020-06-01

Treatment response of advanced HNSCC towards immune checkpoint inhibition is associated with an activated effector memory T cell phenotype

by Max Schumacher, Sina Beer, Emmanuelle Moraes Ribeiro, Fulya Korkmaz, Hildegard Keppeler, Rahel Fitzel, Estelle Erkner, Pia Radszuweit, Claudia Lengerke, Corina Schneidawind, Corina Schneidawind, Sebastian Hoefert, Sebastian Hoefert, Paul Stefan Mauz, Paul Stefan Mauz, Dominik Schneidawind, Dominik Schneidawind, Dominik Schneidawind
Published 2024-03-01